Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
[quote alias=Flatlander id=12291349 date=202004041904] [...] I tend to agree. At one point I think the assay development turnaround time may have been shorter at BCART, based on the Emergency Use Ebola cartridge released in 2016. However, this may have provided BCART a valuable lesson that it wasn't worth chasing infectious disease outbreaks. I doubt that they ever recouped the investment or got that much name recognition from the effort. That said, I suspect that ImmunExpress is pressing the FDA for expedited approval of Septicyte Rapid for use in Triaging patients. Based on news flow it seems like the FDA is approving several COVID 19 related tests per week. FL [/qu ote] Een versnelde goedkeuring van de FDA zou natuurlijk ook zeer mooi en relevant zijn.Het zou ook een enorme trigger zijn om de koers van Biocartis een opstoot te geven,en zodoende die shorters voorgoed het zwijgen op te leggen.
Het coronavirus brengt de ziekenhuizen in grote financiële problemen, zonder dat er buffers zijn om de schok op te vangen.www.tijd.be/politiek-economie/belgie/...
Insider Buying? Section 4 of the Annual Report identifies the number of shares held by various executive team members. It appears that many of the shares (for instance granted to Board members) were acquired via options from BCART as part of the remuneration program that have vested. Verrelst has 1.2 million shares. Were any of these shares purchased recently on the open market? Does anyone have a link to a site (similar to the SEC.gov) that tracks insider activity on the Brussels listed equities? It seems at the present SP, insider buying would help portray that management is confident in the magnitude of the 2021 acceleration. Thanks FL
Verrelst verkreeg 2x670000 0pties/warrants in het kader van verloningsbeleid Biocartis.Melding fsma 16/10/2017
Flatlander schreef op 6 april 2020 14:50 :
Insider Buying?
Section 4 of the Annual Report identifies the number of shares held by various executive team members. It appears that many of the shares (for instance granted to Board members) were acquired via options from BCART as part of the remuneration program that have vested. Verrelst has 1.2 million shares. Were any of these shares purchased recently on the open market? Does anyone have a link to a site (similar to the SEC.gov) that tracks insider activity on the Brussels listed equities? It seems at the present SP, insider buying would help portray that management is confident in the magnitude of the 2021 acceleration.
Thanks
https://www.fsma.be/nl/transaction-search?field_issuer_tid=6974&submit=Zoekenstori.fsma.be/Pages/Search.aspx?PageI...
Flatlander schreef op 6 april 2020 14:50 :
... insider buying would help portray that management is confident in the magnitude of the 2021 acceleration.
Thanks
FL
FL what order of magnitude would a 2021 acceleration look like, in your opinion? 400,000 cartridges sold, or more? or less? BL
Personally I think Biocartis should invest in its infectious disease pipeline. However it should be part of a solid marketing strategy and not based on opportunities. The Ebola test was driven by Rudi Pauwels who has written history before Tibotec was bought by JNJ. It did generate sales but the critical mass in assays was to small. But where do you start. BCART doesn’t have unlimited resources. But think about what Idylla can offer if you would decentralize the triage and create an international diagnostic grid. Anonymus for all I care, but real-time. I can assure you with the precision PCR can offer, the ease of use of Idylla and the idea of creating a 2.0 GP ... you would solve a lot of challenges we are facing today. And although Covid-19 already is a dangerous virus due to various reasons, it can be worse. I think this event should make policy makers and health care professionals re-think about the value of testing. Everybody is focusing on oncology because that sounds sexy to a lot of institutional investors, but please do not forget infectious diseases. I think the latest developments & partnerships are promising for a bright future for Biocartis! They should pick a fight with the big suppliers of central labs, but re-invent the model of diagnostic testing and monitoring. And a well trained GP can do so much more than just ‘guessing’ with the right tools. Keep safe!
Vandaag nieuwe vacature: Senior scientist.
Er staat nog heel wat open bij Biocartis. www.linkedin.com/company/biocartis/
Een TOP financiele directeur is natuurlijk prioriteit voor ons.
Zo, gisteren ingestapt. De weg naar 4Eur lijkt ingeslagen, kunnen we eens een Pharnext dagje meemaken?
M /// schreef op 6 april 2020 20:24 :
Personally I think Biocartis should invest in its infectious disease pipeline. However it should be part of a solid marketing strategy and not based on opportunities. The Ebola test was driven by Rudi Pauwels who has written history before Tibotec was bought by JNJ. It did generate sales but the critical mass in assays was to small. But where do you start. BCART doesn’t have unlimited resources.
But think about what Idylla can offer if you would decentralize the triage and create an international diagnostic grid. Anonymus for all I care, but real-time. I can assure you with the precision PCR can offer, the ease of use of Idylla and the idea of creating a 2.0 GP ... you would solve a lot of challenges we are facing today. And although Covid-19 already is a dangerous virus due to various reasons, it can be worse.
I think this event should make policy makers and health care professionals re-think about the value of testing.
Everybody is focusing on oncology because that sounds sexy to a lot of institutional investors, but please do not forget infectious diseases. I think the latest developments & partnerships are promising for a bright future for Biocartis! They should pick a fight with the big suppliers of central labs, but re-invent the model of diagnostic testing and monitoring. And a well trained GP can do so much more than just ‘guessing’ with the right tools.
Keep safe!
M Infectious disease is pretty crowded, and there are several point of care systems that BCART would have to compete head to head with (Cepheids GenExpert, Abbot's ID Now or Alere, Biofire film array, Roche Molecular Systems, Qiagen, etc.). Alternatively, the Oncology Point of Care sample to answer market is currently wide open. Therefore, I think they are correct to focus on oncology. If a large partner (say Wonfu) wants to expend resources to develop infectious disease content to run on the Idylla platform, I think BCART should amend the partnership to allow them a greater portion of profits/royalties to cover their investment for that content. However, in the meantime I think BCART needs to maintain focus to conserve resources. Your point on "critical mass" is a good one. While partners have signed up to launch content on Idylla, EXAS has delayed recently in proceeding with OncoType Dx validation studies. Reportedly, they are assessing the go to market launch for the EU and ROW. It is quite possible that they are waiting to see more demonstration of console placements to resolve the critical mass issue. BCART is in a bit of "a chicken or the egg situation". They need good content to drive console placements and they need the console placements to make the platform more attractive to content partners. This is not unique in that Cepheid had a similar pace to their GenExpert system roll out. As we have pointed out, Cepheids growth has continued at better than 20% for more than a decade. You seem to have a good understanding of BCART's history. That perspective is always needed. Welcome to the Board! FL
brightlight schreef op 6 april 2020 17:44 :
[...]
FL
what order of magnitude would a 2021 acceleration look like, in your opinion? 400,000 cartridges sold, or more? or less?
BL
BL With Coronavirus raging throughout the world, I think 2020 cartridges in the range of 230,000 would be an accomplishment. Assuming the virus is under control or management strategies are adopted that allow somewhat normal life activities, I'd look for at least 75% growth in 2021 (403,000). This is based on receipt of two diagnostic use approvals in the US and registration of some (MSI, KRAS, etc) content in Japan during the first half of 2021. Idylla has experienced growth spurts (70% or more) when they introduce the product as a RUO tool to a new geographic market. The diagnostic use designation would unlock the much bigger POC market resulting in more sustained cartridge use. China is a big variable. There has been little guidance on when sales would ramp there, so I have really not factored it in to any extent. I first started investing in BCART feeling 2020 would be the year. Approvals and launches got pushed back, so I shifted to 2021 being the year. Now Coronavirus makes it more likely to be 2022 and beyond. Unfortunately, that probably means another round of financing before profitability. The market upheaval has created other opportunities, so I'm not adding to my BCART position. I'd like to see some insiders buying as a sign of better things to come. As I have said before, I'm committed to sticking it out through the POC introduction in the US and probably Asia. If it develops the kind of traction I believe it is capable of, it could be a great long term holding as the oncology MDx market will grow for decades. However, in the current market, BCART can only be viewed as a speculation at a time when the market is demanding sound balance sheets and proven market performance. Regards FL
Why hold a physical Annual Meeting in the current Coronavirus environment?finance.yahoo.com/news/press-release-... I think they should go with a virtual Annual meeting. I'm a shareholder in Alcon (spun out from Novartis) and they just announced there will be no physical meeting. FL
Flatlander schreef op 7 april 2020 18:31 :
[...]
BL
With Coronavirus raging throughout the world, I think 2020 cartridges in the range of 230,000 would be an accomplishment. Assuming the virus is under control or management strategies are adopted that allow somewhat normal life activities, I'd look for at least 75% growth in 2021 (403,000). This is based on receipt of two diagnostic use approvals in the US and registration of some (MSI, KRAS, etc) content in Japan during the first half of 2021. Idylla has experienced growth spurts (70% or more) when they introduce the product as a RUO tool to a new geographic market. The diagnostic use designation would unlock the much bigger POC market resulting in more sustained cartridge use. China is a big variable. There has been little guidance on when sales would ramp there, so I have really not factored it in to any extent..
Regards FL
FL It is good to know we both see the 400,000 mark as not entirely unrealistic for 2021. I noticed the Wondfo-cartis website is already up and running with 9 tests on offer (RUO). I would suspect the same 9 tests will be offered in Japan, although Nichirei does not yet show any sign of Biocartis on their website. I suspect these will be the major growth drivers for this year, together with the Septicyte test: www.grandviewresearch.com/press-relea... Concerning US diagnostic designation, as it now stands only one PMA will be submitted in Q4 2020 and 2 more in Q1 2021. And then there is the Septicyte US diagnostic designation which is expected in Q3 2020 if I am not mistaken. Whether the ramp up in 2021 can still happen will largely depend on how long the FDA will take to process the PMA's. I don't have the faintest idea about that. Also let's not forget Septicyte sales may surprise us in positive way for 2021. BL
Alweer 2 nieuwe vacatures. Een Quality Assurance manager Development. Een R&D Project Manager Product Development. Er is blijkbaar veel beweging gaande daar in Mechelen.
joe123 schreef op 8 april 2020 09:39 :
Alweer 2 nieuwe vacatures.
Een Quality Assurance manager Development.
Een R&D Project Manager Product Development.
Er is blijkbaar veel beweging gaande daar in Mechelen.
Mooi als dat allemaal nieuwe vacatures zijn. Zou ook kunnen wijzen op heel veel verloop... Moeten we dit als positief bekijken? Anderzijds op paar dagen wel mooie opwaartse beweging. Zachtjes naar de 4 en daarna hopelijk 5 :)
Nestel95 schreef op 8 april 2020 09:54 :
[...]
Mooi als dat allemaal nieuwe vacatures zijn. Zou ook kunnen wijzen op heel veel verloop...
Moeten we dit als positief bekijken?
Anderzijds op paar dagen wel mooie opwaartse beweging. Zachtjes naar de 4 en daarna hopelijk 5 :)
Hopelijk snel maal drie.Dan zit ik terug aan mijn aankoopkoers en tevens introductiekoers van de beursgang van Biocrtis.Het was toen de beloftevolste beursintroductie van jaren.Ik heb er al veel geduld mee gehad,dus nog een jaar of vijf kan er nog wel bij.
Rarezot schreef op 16 januari 2020 09:37 :
[...]
Ja ik ben aandeelhouder. Ingestapt toen ik de technologie zag van de tweede lijn. Echt de meest impressionante lijn dat ik ooit aan heb gewerkt. Mijn aandeel is sterk vergroot na de dip, maar ik heb nog steeds verlies.
En ook de mentaliteit van de medewerkers was een van de beste dat ik al heb gezien. Tuurlijk waren er onderling soms wat wrijvingen, maar iedereen waar ik mee in contact kwam was zeer begaan met het bedrijf en erg gemotiveerd.
Het bedrijf heeft visie, ze werken er gezamelijk naartoe en het is een product waar ik achter sta.
Groeten,
Rarezot
Hiermee is mijn mening dat het verloop wel zal meevallen.Wat Rarezot hierbij schrijft geeft mij veel vertrouwen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee